LDS/Medical Tests/Early Bladder Cancer Detection and Surveillance Methylation Test (Bladder CARE™)

Early Bladder Cancer Detection and Surveillance Methylation Test (Bladder CARE™)

Bladder cancer is the sixth most common cancer in the United States, with more than 80,000 new cases annually. Non-muscle-invasive bladder cancer (NMIBC) accounts for ~70% of cases and, while associated with favorable survival, it has a recurrence rate as high as 60–70%, requiring lifelong surveillance. Current guidelines rely on cystoscopy, an invasive and costly procedure, combined with urine cytology, which has limited sensitivity, particularly for low-grade tumors. Upper tract urothelial carcinoma (UTUC) comprises 5–7% of urothelial cancers, and up to 50% of UTUC patients develop subsequent bladder cancer. Diagnosis of UTUC is challenging, with poor performance of urine cytology and cystoscopy; many patients require ureteroscopy, an invasive diagnostic approach.

Bladder CARE™ is a non-invasive, urine-based epigenetic assay designed to detect bladder cancer and UTUC. The test quantitatively measures DNA methylation at three validated biomarkers (tRNA-Cys, SIM2, and NKX1-1) using next-generation sequencing (NGS) and a proprietary diagnostic algorithm. Results are expressed as the Bladder CARE™ Index (BCI), a score proportional to the abundance of cancer-derived DNA in the urine. Clinical validation studies in collaboration with Zymo Research Corp. and USC Norris Comprehensive Cancer Center demonstrated a sensitivity of 93.5% and specificity of 92.6% for detecting bladder cancer.

The assay is intended to be used in conjunction with current standard diagnostic procedures, as an aid for the initial diagnosis of bladder cancer and UTUC for patients presenting with hematuria and suspected of having bladder cancer and UTUC.

  • As an aid for the initial diagnosis of bladder cancer for patients presenting with hematuria and suspected of having bladder cancer
  • As and aid in the diagnosis of upper tract urothelial carcinoma for patients presenting with hematuria and suspected of having bladder cancer and UTUC

Positive
BCI 2.5–10.0: Low positive, indicates increased risk of bladder cancer or UTUC.
BCI > 10.0: Strong probability of bladder cancer or UTUC; confirmatory cystoscopy or biopsy recommended.

Negative
BCI < 2.5: Low likelihood of bladder cancer or UTUC.

Clinical Note: Test results should be interpreted alongside clinical presentation, cystoscopy, cytology, and imaging studies.

BCI < 2.5 (Negative)

Next Generation Sequencing with Methylation assay with proprietary algorithm calculates bladder CARE™ Index (BCI).

Specimen Type: Urine. Urine samples collected at home or in clinic using the Pangea Urine Collection Kit Immediately mix with provided Urine Preservation Reagent to protect DNA integrity.

Stability

  • Ambient: up to 28 days.
Bladder biopsy, Urovysion, Urinalysis, Urine culture, Urine cytology.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Urol. 2023 May;209(5):854-862. [PMID: 36795966]
  • Clin Epigenetics. 2021 Apr 21;13(1):84. [PMID: 33882992]
  • Urol Oncol. 2020 Jun;38(6):603.e1-603.e7. [PMID: 32081560]
  • Clin Epigenetics. 2018 May 30;10:71. [PMID: 29854012]
  • J Clin Med. 2024 Nov 26;13(23):7159. [PMID: 39685620]
  • Pangea Laboratory. Bladder CARE™ Test Information. https://pangealab.com/bladder-care/
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login